Table 4.

Clinical trials of PDT for urological cancers

Photosensitizers	Conditions	Locations	Status	NCT number
TLD1433	NMIBC refractory to BCG	Canada	Phase 1 (C)	NCT03053635
	NMIBC refractory to BCG	United States; Canada	Phase 2 (R)	NCT03945162
Photofrin®	Superficial BC	United States	Phase 1/2 (C)	NCT00322699
Hexvix®	Intermediate or high-risk BC	NA	Phase 1 (C)	NCT01303991
Motexafin Lutetium	Adenocarcinoma of the prostate; recurrent PCa; stage I PCa; stage IIA PCa; stage IIB PCa	United States	Phase 1 (T)	NCT00005067
WST09	PCa	Canada	Phase 2 (C)	NCT00305929
	Recurrent or persistent localized carcinoma of the prostate following radiation therapy failure	Canada	Phase 2 (C)	NCT00308919
	PCa	Canada	Phase 2/3 (T)	NCT00312442
WST11	PCa	Canada; France; United Kingdom	Phase 2 (C)	NCT00707356
	PCa	United States	Phase 1/2 (C)	NCT00946881
	PCa	France; Netherlands; United Kingdom	Phase 2 (C)	NCT00975429
	PCa	Belgium; Finland; France; Germany; Italy; Netherlands; Spain; Sweden; Switzerland; United Kingdom	Phase 3 (C)	NCT01310894
	PCa	Mexico; Panama; Peru	Phase 3 (C)	NCT01875393
	Localized PCa	United States	Phase 2 (ANR)	NCT03315754
	Low Risk PCa	France	Phase 4 (T)	NCT03849365
	Localized PCa	United States	Phase 3 (W)	NCT04225299
	Upper tract urothelial carcinoma	United States	Phase 1 (ANR)	NCT03617003
	Renal cancer	United Kingdom	Phase 1/2 (T)	NCT01573156
	Transitional cell cancer of renal pelvis and ureter	United States; France	Phase 3 (R)	NCT04620239
Verteporfin	Recurrent PCa	United States; Canada; United Kingdom	Phase 1 (U)	NCT03067051

Data obtained from clinicaltrials.gov (Accessed on April 13, 2022)

NA Not available; C Completed; R: Recruiting; T Terminated; ANR active, not recruiting; W Withdrawn; U Unknown; NMIBC Non-muscle invasive bladder cancer; BC Bladder cancer; PCa Prostate cancer